Advances in antibody-drug conjugate in the treatment of urothelial carcinoma

Abstract:

Urothelial carcinoma（UC） is a common malignancy of the urological system. Under a variety of treatment measures，such as surgery，chemotherapy and immunotherapy，some patients still suffer disease recurrence and metastasis，leading to poor prognosis. Antibody-drug conjugate（ADC） combining the targeting of antibody drugs and the cytotoxicity of chemotherapeutic drugs，has recently become a research hotspot for individualized precision treatment of cancer and a new choice for these patients. At present，the clinical trials related to ADC in the treatment of UC have achieved fruitful results. Enfortomab Vedotin targeting Nectin-4，Sacituzumab Govitecan targeting TROP-2，and Disitamab Vedotin targeting HER-2 have been approved to be applied in clinical practice，and new ADCs for other targets have also begun to emerge. This article intends to review the latest research in this field.